JP6298998B2 - ウイルス感染を治療するための1,2,4−トリアジン誘導体 - Google Patents

ウイルス感染を治療するための1,2,4−トリアジン誘導体 Download PDF

Info

Publication number
JP6298998B2
JP6298998B2 JP2015533635A JP2015533635A JP6298998B2 JP 6298998 B2 JP6298998 B2 JP 6298998B2 JP 2015533635 A JP2015533635 A JP 2015533635A JP 2015533635 A JP2015533635 A JP 2015533635A JP 6298998 B2 JP6298998 B2 JP 6298998B2
Authority
JP
Japan
Prior art keywords
alkyl
carboxylic acid
compound
heteroarylalkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015533635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535839A (ja
JP2015535839A5 (cg-RX-API-DMAC10.html
Inventor
ヴァンサン・ジェムバス
フィリップ・ジュボー
クリストフ・オアロ
ヴァンサン・レヴァシェ
ジャン−フランソワ・ボンファンティ
ダヴィド・グレイグ・マク・ゴーワン
ジェローム・エミール・ジョルジュ・ギーユモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rouen
Original Assignee
Universite de Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Rouen filed Critical Universite de Rouen
Publication of JP2015535839A publication Critical patent/JP2015535839A/ja
Publication of JP2015535839A5 publication Critical patent/JP2015535839A5/ja
Application granted granted Critical
Publication of JP6298998B2 publication Critical patent/JP6298998B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
JP2015533635A 2012-10-01 2013-10-01 ウイルス感染を治療するための1,2,4−トリアジン誘導体 Expired - Fee Related JP6298998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306196.2 2012-10-01
EP12306196.2A EP2712866A1 (en) 2012-10-01 2012-10-01 1,2,4-triazine derivatives for the treatment of viral infections
PCT/EP2013/070488 WO2014053516A1 (en) 2012-10-01 2013-10-01 1,2,4-triazine derivatives for the treatment of viral infections.

Publications (3)

Publication Number Publication Date
JP2015535839A JP2015535839A (ja) 2015-12-17
JP2015535839A5 JP2015535839A5 (cg-RX-API-DMAC10.html) 2016-11-10
JP6298998B2 true JP6298998B2 (ja) 2018-03-28

Family

ID=46982496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533635A Expired - Fee Related JP6298998B2 (ja) 2012-10-01 2013-10-01 ウイルス感染を治療するための1,2,4−トリアジン誘導体

Country Status (21)

Country Link
US (1) US9416114B2 (cg-RX-API-DMAC10.html)
EP (2) EP2712866A1 (cg-RX-API-DMAC10.html)
JP (1) JP6298998B2 (cg-RX-API-DMAC10.html)
KR (1) KR102138393B1 (cg-RX-API-DMAC10.html)
CN (1) CN104812747B (cg-RX-API-DMAC10.html)
AU (1) AU2013326579B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015007310B1 (cg-RX-API-DMAC10.html)
CA (1) CA2886630C (cg-RX-API-DMAC10.html)
CL (1) CL2015000787A1 (cg-RX-API-DMAC10.html)
EA (1) EA026236B1 (cg-RX-API-DMAC10.html)
ES (1) ES2616496T3 (cg-RX-API-DMAC10.html)
IL (1) IL237871A (cg-RX-API-DMAC10.html)
IN (1) IN2015DN03327A (cg-RX-API-DMAC10.html)
MX (1) MX348229B (cg-RX-API-DMAC10.html)
MY (1) MY182558A (cg-RX-API-DMAC10.html)
NZ (1) NZ706354A (cg-RX-API-DMAC10.html)
PH (1) PH12015500724B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201502522WA (cg-RX-API-DMAC10.html)
UA (1) UA114644C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014053516A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201502240B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6046694B2 (ja) 2011-04-08 2016-12-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療用のピリミジン誘導体
ES2690082T3 (es) 2011-11-09 2018-11-19 Janssen Sciences Ireland Uc Derivados de purina para el tratamiento de infecciones virales
SI2872515T1 (sl) 2012-07-13 2016-10-28 Janssen Sciences Ireland Uc Makrociklični purini za zdravljanje virusnih infekcij
TR201807076T4 (tr) 2012-10-10 2018-06-21 Janssen Sciences Ireland Uc Viral enfeksiyonların ve diğer hastalıkların tedavisine yönelik pirolo[3,2-d]pirimidin derivatları.
CA2886635C (en) 2012-11-16 2021-01-05 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
MX366481B (es) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
EA034674B1 (ru) 2013-05-24 2020-03-05 Янссен Сайенсиз Айрлэнд Юси Производные пиридона для лечения нарушений, в которое вовлечены модуляции tlr7 и/или tlr8
CN109369643B (zh) 2013-06-27 2021-05-18 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
CN105492446B (zh) 2013-07-30 2018-08-03 爱尔兰詹森科学公司 用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
CA3027471A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
EA038646B1 (ru) * 2016-09-29 2021-09-28 Янссен Сайенсиз Айрлэнд Анлимитед Компани Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
BR112021015577A8 (pt) 2019-02-08 2021-10-05 Research & Business Found Sungkyunkwan Univ Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
JP7690222B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的制御が可能なアジュバントを含むmRNAワクチン
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
WO2024151953A1 (en) * 2023-01-15 2024-07-18 Viradem Inc. Compounds and methods for treating diseases caused by sars-cov-2 and other coronaviruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485531A1 (fr) * 1980-06-25 1981-12-31 Fabre Sa Pierre Nouveaux n-oxydes de diaryl-5,6 as triazines 1-2-4, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
EP0882727B9 (en) 1996-07-03 2005-06-15 Sumitomo Pharmaceuticals Company, Limited Novel purine derivatives
JP4375901B2 (ja) 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
CN101035773B (zh) * 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
CN101203519A (zh) 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物
JP4850911B2 (ja) * 2005-09-01 2012-01-11 エフ.ホフマン−ラ ロシュ アーゲー P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン
RU2352565C1 (ru) * 2007-10-08 2009-04-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" 3-амино-6-ароилметил-5-гидрокси-1,2,4-триазины и способ их получения
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease

Also Published As

Publication number Publication date
PH12015500724A1 (en) 2015-06-01
AU2013326579B2 (en) 2017-04-27
KR20150084791A (ko) 2015-07-22
KR102138393B1 (ko) 2020-08-14
CL2015000787A1 (es) 2015-10-02
IN2015DN03327A (cg-RX-API-DMAC10.html) 2015-10-09
US20150336907A1 (en) 2015-11-26
EA026236B1 (ru) 2017-03-31
MX348229B (es) 2017-05-31
EP2903976B1 (en) 2016-12-07
WO2014053516A1 (en) 2014-04-10
HK1208223A1 (en) 2016-02-26
EP2903976A1 (en) 2015-08-12
ZA201502240B (en) 2016-05-25
ES2616496T3 (es) 2017-06-13
UA114644C2 (uk) 2017-07-10
JP2015535839A (ja) 2015-12-17
NZ706354A (en) 2018-08-31
CN104812747B (zh) 2017-03-08
CA2886630A1 (en) 2014-04-10
BR112015007310A2 (pt) 2017-08-08
CN104812747A (zh) 2015-07-29
PH12015500724B1 (en) 2015-06-01
MY182558A (en) 2021-01-25
US9416114B2 (en) 2016-08-16
BR112015007310B1 (pt) 2022-07-19
SG11201502522WA (en) 2015-05-28
EA201500383A1 (ru) 2015-07-30
AU2013326579A1 (en) 2015-04-09
EP2712866A1 (en) 2014-04-02
MX2015004160A (es) 2016-02-05
IL237871A (en) 2017-04-30
CA2886630C (en) 2021-01-26

Similar Documents

Publication Publication Date Title
JP6298998B2 (ja) ウイルス感染を治療するための1,2,4−トリアジン誘導体
KR102217111B1 (ko) 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
DK2812331T3 (en) PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
KR102216479B1 (ko) 바이러스 감염 또는 추가 질환의 치료를 위한 알킬피리미딘 유도체
KR102225233B1 (ko) 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
JP6336036B2 (ja) ウイルス感染治療のための大環状デアザプリノン
AU2018274911A1 (en) Pyrrolo[3,2-c]Pyrimidine derivatives for the treatment of viral infections and other diseases
AU2014270418B2 (en) Pyridone derivatives for the treatment of viral infections and further diseases
HK1208223B (en) 1,2,4-triazine derivatives for the treatment of viral infections
HK40003405A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
HK1209412B (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180130

R150 Certificate of patent or registration of utility model

Ref document number: 6298998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees